According to our latest study on "Human Vaccine Adjuvants Market Size and Forecasts (2020 - 2030), Global and Regional Share, Trends, and Growth Opportunity Analysis," the market is expected to grow from US$ 1,571.41 million in 2022 and is expected to reach US$ 4,489.23 million by 2030; it is anticipated to record a CAGR of 10.7% from 2022 to 2030. The report highlights the key factors driving the human vaccine adjuvants market growth and prominent players with their developments in the market.
Adjuvants are important components in vaccine formulation as they help strengthen the body's immune response to antigens, ultimately contributing to vaccine effectiveness. Adjuvants can range from simple synthesized small molecule compounds to complicated natural extracts and particulates. Key factors driving the human vaccine adjuvants market growth include the rising prevalence of chronic diseases and the growing focus on immunization programs.
The human vaccine adjuvants market is segmented based on type into particulate adjuvants, emulsion adjuvants, combination adjuvants, and others. The particulate adjuvant segment held a larger share of the market in 2022. However, the emulsion adjuvants segment is expected to register a higher CAGR in the market from 2022 to 2030. Particulate adjuvants consist of particles, often of nanometer or micrometer size, designed to mimic pathogens or cellular structures, stimulating a robust immune response. These adjuvants enhance antigen uptake by immune cells and promote immune activation. Notable examples of particulate adjuvants include aluminum salts (Alum), which have been used for decades in human vaccines to enhance antibody responses, and newer developments such as virus-like particles (VLPs) and nanoparticle-based adjuvants.
By application, the human vaccine adjuvants market is segmented into influenza, hepatitis, human papillomavirus (HPV), and others. The influenza segment held the largest share of the market in 2022 and is expected to register the highest CAGR in the market from 2022 to 2030. Influenza vaccines are crucial for preventing seasonal flu outbreaks and potential pandemics. They target a rapidly evolving virus, requiring continual vaccine updating to match circulating strains. Adjuvants used in influenza vaccines enhance immune responses, particularly in high-risk populations such as the elderly or immunocompromised individuals. They also support the development of broadly protective, cross-reactive immune responses.
In terms of end user, the human vaccine adjuvants market is segmented into pharmaceutical and biotechnology companies, CMOs and CROs, and others. The pharmaceutical and biotechnology companies segment held the largest share of the market in 2022 and is expected to register the highest CAGR in the market from 2022 to 2030. Pharmaceutical and biotechnology companies play a central role in the research, development, and commercialization of vaccines, including adjuvanted vaccine formulations, targeting diverse infectious diseases and health conditions. These companies are at the forefront of vaccine innovation, driving the discovery and optimization of adjuvant technologies, vaccine candidates, and adjuvanted vaccine formulations through preclinical and clinical development stages.
Novartis AG, Dynavax Technologies Corp, CSL Ltd, Seppic SA, SPI Pharma Inc, Hawaii Biotech Inc, Croda International Plc, Novavax Inc, Phibro Animal Health Corp, and Creative Biolabs Inc are among the leading companies operating in the global Human Vaccine Adjuvants market.
Companies operating in the human vaccine adjuvants market adopt various organic and inorganic strategies. Organic strategies mainly include product launches and product approvals. Acquisitions, collaborations, and partnerships are among the inorganic growth strategies witnessed in the human vaccine adjuvants market. These growth strategies allow the market players to expand their businesses and enhance their geographic presence, thereby contributing to the overall human vaccine adjuvants market growth. Further, acquisition and partnership strategies help them strengthen their customer base and expand their product portfolios.
A few of the significant developments by key market players are listed below.
- In December 2023, Health Canada approved a supplement to a New Drug Submission for Novavax Inc's Nuvaxovid as a primary series of two doses for adolescents aged 12 to 17 years.
- In November 2023, Seppic launched MONTANIDE GEL P PR, an aqueous adjuvant based on a polymeric technology exclusively dedicated to avian injectable vaccines, meeting the need for innocuity in the avian market. In addition, MONTANIDE GEL P PR is particularly stable and can resist destabilizing antigenic media frequently used in avian vaccines.
- In October 2023, SPI Pharma Inc. and Q-Vant Biosciences Inc. announced a partnership that combines Q-Vant's leadership in sustainable saponin extraction technology with SPI's global reach and servicing expertise in the pharmaceutical industry. The arrangement includes investment in the expansion of Q-Vant's proprietary 100% sustainable Q-SAP technology and an exclusive commercial agreement to accelerate the global adoption of their saponin adjuvants for veterinary and human vaccine formulations.
- In January 2023, Novavax Inc. partner SK Bioscience received expanded manufacturing and marketing approval from the Korean Ministry of Food and Drug Safety ("KMFDS") for Nuvaxovid for use as a booster in adults aged 18 and older.
Contact Us
Contact Person: Sameer Joshi
Phone: +1-646-491-9876
Email Id: sales@premiummarketinsights.com